NL-OMON34490已完成不适用
EVALUATION OF SAFETY, TOLERABILITY AND PHARMACOKINETIC CHARACTERISTICS OF MULTIPLE-ASCENDING DOSES OF CG400549 IN HEALTHY VOLUNTEERS - CG400549 Multiple ascending dose study
Crystal Genomics0 个研究点目标入组 24 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Age: 18-55 years, inclusive
- •BMI: 19-30 kg/m2
- •No relevant deviations at screening
排除标准
- •Suffering from: hepatitis B, cancer or HIV/AIDS.
- •In case of participation in another drug study within 60 days before the start of this study or being a blood donor (50 mL or more) within 60 days from the start of the study. In case of donating more than 1.5 liters of blood (for men) / more than 1.0 liters of blood (for women) in the 10 months preceding the start of this study.
研究者
相似试验
已完成
不适用
Assessment of safety, tolerability and pharmacokinetics of single and multiple ascending oral doses of GLPG2451 and of the combination of GLPG2451 and GLPG2222 in healthy female subjects.cystic fibrosisTaaislijmziekte, cystische fibroseNL-OMON42997Galapagos SAS56
已完成
不适用
Pharmacokinetics and safety of DA-6034KCT0000793Dong-A Pharm67
已完成
不适用
Evaluation of the safety, tolerability, pharmacokinetics and pharmacodynamics of topically applied NT-077 (tiotropium bromide) in healthy volunteers.hyperhydrosisprimary hyperhidrosis is a not well-delineated conditionexcessive sweat productionNL-OMON50872otoxins Holding B.V.4
已完成
不适用
Assessment of safety, tolerability, pharmacokinetics and pharmacodynamics of multiple oral doses of the combination of GLPG2451 and GLPG2222, with or without GLPG2737, in adult subjects with cystic fibrosisgenetic diseasethick mucus disease10083624NL-OMON46421Galapagos NV6
已完成
不适用
Evaluating the safety, tolerability, and pharmacodynamic properties of IW-6463 in healthy elderly subjects.Alzheimer's diseaseDementiaNL-OMON48314Cyclerion Therapeutics, Inc.24